ONVO - Organovo Holdings, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.28
-0.04 (-3.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.32
Open1.31
Bid1.26 x 500
Ask1.35 x 200
Day's Range1.26 - 1.35
52 Week Range0.91 - 2.42
Volume1,020,308
Avg. Volume1,118,449
Market Cap142.243M
Beta2.30
PE Ratio (TTM)N/A
EPS (TTM)-0.32
Earnings DateAug 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.67
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Free Pre-Market Technical Recap on ResMed and Three Additional Healthcare Stocks

    On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.

  • GlobeNewswire3 days ago

    Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results

    SAN DIEGO, July 19, 2018-- Organovo Holdings, Inc. will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time to discuss the Company's fiscal first-quarter 2019 operating and financial ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ONVO earnings conference call or presentation 31-May-18 9:00pm GMT

    Q4 2018 Organovo Holdings Inc Earnings Call

  • Here's Why Organovo Holdings Stock Fell as Much as 28.4% Today
    Motley Fool2 months ago

    Here's Why Organovo Holdings Stock Fell as Much as 28.4% Today

    The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.

  • Associated Press2 months ago

    Organovo: Fiscal 4Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...

  • GlobeNewswire2 months ago

    Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019

    -Lead Investigational New Drug program for Alpha-1-antitrypsin deficiency received FDA’ s orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019. -Second IND-track program ...

  • Benzinga2 months ago

    Organovo Q4 Earnings Preview

    On Thursday, Organovo Holdings (NYSE: ONVO ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Organovo EPS ...

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Organovo Holdings and Three Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.

  • Want To Invest In Organovo Holdings Inc (NASDAQ:ONVO)? Here’s How It Performed Lately
    Simply Wall St.2 months ago

    Want To Invest In Organovo Holdings Inc (NASDAQ:ONVO)? Here’s How It Performed Lately

    After reading Organovo Holdings Inc’s (NASDAQ:ONVO) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past andRead More...

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals, Diamondrock Hospitality, and Organovo — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tyson ...

  • GlobeNewswire2 months ago

    Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results

    Organovo Holdings, Inc. (ONVO) (“Organovo”) will host a conference call on Thursday, May 31, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal fourth-quarter 2018 financial results. In advance of the call on May 31, 2018, Organovo will issue its fiscal fourth-quarter 2018 earnings press release, which will be available at http://www.organovo.com.

  • GlobeNewswire2 months ago

    Organovo to Present New Preclinical Data for Its Liver Therapeutic Tissue IND-Track Programs at the World Advanced Therapies and Regenerative Medicine Congress

    Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that it will present new preclinical data showing the strong functionality of its liver therapeutic tissue in a second IND-track program for Type 1 Tyrosinemia.  This data will be presented at the World Advanced Therapies and Regenerative Medicine Congress in London on May 18, 2018 by Benjamin Shepherd, Ph.D., Senior Director of Therapeutics, at Organovo. Type 1 Tyrosinemia is a rare disease characterized by a patient’s inability to metabolize the amino acid tyrosine due to a deficiency of the enzyme fumarylacetoacetate hydrolase.  This disorder frequently causes severe liver damage, with current treatment options often limited to organ transplantation.  Organovo recently studied the potential benefit of its NovoTissues® in an established animal model for Type 1 Tyrosinemia, and showed retention and sustained functionality post-implamantation.  Pathologic evaluation of the diseased animals receiving implanted bioprinted liver tissues also suggested an improvement in liver health and extended survival versus non-treated animals.

  • GlobeNewswire3 months ago

    Organovo and Samsara Sciences Partner with New Manufacturing USA Institute

    Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities.  As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead BiofabUSA on behalf of the Department of Defense. Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the US relative to global competition.  ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.

  • Can The Uptrend Continue for Organovo Holdings (ONVO)?
    Zacks3 months ago

    Can The Uptrend Continue for Organovo Holdings (ONVO)?

    Investors certainly have to be happy with Organovo Holdings, Inc. (ONVO) and its short term performance

  • Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH
    PR Newswire3 months ago

    Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH

    Late-Breaking Poster Presented at The International Liver Congress SAN DIEGO and KALAMAZOO, Mich. , April 12, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it presented a late-breaking ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ONVO earnings conference call or presentation 8-Feb-18 10:00pm GMT

    Q3 2018 Organovo Holdings Inc Earnings Call

  • Associated Press5 months ago

    Organovo reports 3Q loss

    The San Diego-based company said it had a loss of 7 cents per share. The development-stage company focused on commercializing functional human tissue for drug and biological research posted revenue of ...

  • ACCESSWIRE5 months ago

    Organovo Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 8, 2018 at 5:00 PM Eastern ...